New Nanomechanical Method for Detecting Disease and Treatment-Relevant Genes
News Dec 05, 2006
Researchers from the National Centre of Competence in Research at the Swiss Nanoscience Institute in Basel, together with Roche scientists have developed a method for the detection of disease and treatment-relevant genes.
The results of this research are published in the December issue of the journal Nature Nanotechnology.
Ulrich Certa, Head of Functional Genomics at the Roche Centre for Medical Genomics, comments: “Our research results show that these new nanomechanical sensors can be used for the direct and continuous monitoring of patients’ response to a given treatment.
This promising new technology takes us a step nearer to tailoring treatment directly to patients’ needs, hopefully with ever fewer adverse effects.”
Many different body processes are involved in disease and its treatment.
Gene activities are regulated in varying ways depending on heredity, partly accounting for the often differing individual responses to a given drug. What helps one patient may have no effect on another, or may even have adverse effects.
The new method will detect active genes directly by measuring their transcripts (messenger ribonucleic acid [mRNA]), which represent the intermediate step and link to protein synthesis.
Short complementary nucleic acid segments (sensors) are attached to tiny silicon cantilevers which are only 450 nanometres thick and therefore react with extraordinary sensitivity.
Binding of the targeted gene transcript to its matching counterpart on one of the cantilevers results in optically measurable mechanical bending.
In the paper now published the researchers cite the example of a tumour cell line in which interferon treatment activates an important gene for controlling cell growth to show that this nanomechanical method can be used for rapid gene transcript detection.
Because the method works within minutes, it could be used as a real-time sensor for continuously monitoring biomedical processes.
An array of different gene transcripts can even be measured in parallel by aligning appropriately coated cantilevers alongside each other like the teeth of a comb.
The new method complements current molecular diagnostic techniques such as the gene chip and real-time PCR.
It could be used as a real-time sensor for continuously monitoring various clinical parameters or for detecting rapidly replicating pathogens that make prompt diagnosis essential.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.